Genocea Biosciences Inc. | |
Stock Exchange | Frankfurt Stock Exchange |
EPS |
- |
Market Cap |
- |
Shares Outstanding |
86.63 M |
Public Float |
57.86 M |
Genocea Biosciences Inc. | |
Stock Exchange | NASDAQ Stock Market |
EPS |
$2.32 |
Market Cap |
$94.03 M |
Shares Outstanding |
24.55 M |
Public Float |
26.44 M |
Address |
Cambridge Discovery Park Cambridge Massachusetts 02140 United States |
Employees | - |
Website | http://www.genocea.com |
Updated | 07/08/2019 |
Genocea Biosciences engages in the development and commercialization of cancer vaccines. It uses its proprietary technology platform ATLAS, to identify clinically relevant antigens of T cells based on actual human immune responses. Its product candidates include GEN-003, an investigational immunotherapy for the treatment of genital herpes; and GEN-009, a neoantigen cancer vaccine. |